文献速递免疫规划卫生政策与健康促进

异源与同源疫苗方案:mRNA/LNP初免后SLA佐剂SARS-CoV-2刺突蛋白加强免疫的免疫应答

Heterologous vs. homologous vaccine regimens: Sulfated lactosyl archaeol (SLA) archaeosome-adjuvanted SARS-CoV-2 spike protein boost following an mRNA/LNP prime induces robust and balanced immune responses.
PubMed 文献 · Vaccine · 2026-01-07

该研究在小鼠模型中比较了基于mRNA/LNP和/或硫酸化乳糖基古菌醇(SLA)古菌体佐剂蛋白亚单位疫苗的同源与异源SARS-CoV-2刺突蛋白免疫方案的免疫学结局。结果显示异源方案的IgG1:IgG2c比率反映其初免疫苗,且仅以mRNA/LNP初免的异源方案才诱导强细胞免疫,其CD4+ T细胞活化优于同源mRNA/LNP方案而CD8+ T细胞水平相似。

要点

  • 同源mRNA/LNP方案诱导较强体液应答和CD4+、CD8+ T细胞活化。
  • 同源蛋白亚单位方案以IgG1应答为主,仅诱导较强CD4+ T细胞活化。
  • 异源方案IgG1:IgG2c比率反映初免疫苗,提示免疫印迹可能影响。

核心结论

  • 不同异源疫苗接种方案可诱导不同的免疫学特征,可能影响人群长期结局如SARS-CoV-2免疫力消退。

研究设计与样本

  • 小鼠模型中比较基于mRNA/LNP和/或SLA古菌体佐剂蛋白亚单位疫苗的同源与异源SARS-CoV-2刺突蛋白免疫方案。

主要发现

  • 同源mRNA/LNP方案诱导体液应答,IgG1:IgG2c比率较平衡,伴较强CD4+和CD8+ T细胞活化。
  • 同源蛋白亚单位方案诱导以IgG1为主的应答,仅伴较强CD4+ T细胞活化。
  • 异源方案IgG1:IgG2c比率反映初免疫苗。
  • 异源方案中仅mRNA/LNP初免动物实现强细胞应答,蛋白初免动物未实现。
  • mRNA/LNP初免后异源加强的CD4+ T细胞活化优于同源mRNA/LNP方案,CD8+ T细胞水平相似。

临床怎么用

  • 异源加强免疫选择需考虑初免疫苗平台对细胞免疫应答的影响。

局限性

  • 证据来自小鼠模型,外推至人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To combat the spread of and disease caused by SARS-CoV-2, mRNA/LNP vaccines were introduced into the clinic in 2020 with tremendous uptake and success. Since then, there have been multiple other SARS-CoV-2 vaccines approved across different countries based on various types of platforms including viral vector, inactivated virus and adjuvanted protein subunit vaccines. This has led to a scenario where there is a high probability of heterologous vaccinations in certain populations, whereby booster doses will differ from the initial vaccine formulations they received. We have previously demonstrated the immunogenicity of sulfated lactosyl archaeol (SLA) archaeosome-adjuvanted protein subunit vaccines and mRNA/LNPs in preclinical models within separate studies. Herein, we compared the immunological outcomes following homologous and heterologous vaccination regimens against SARS-CoV-2 spike based on mRNA/LNPs and/or SLA archaeosome-adjuvanted protein subunit vaccines in a mouse model. The homologous mRNA/LNP regimen induced a strong humoral response consisting of a more balanced IgG1:IgG2c ratio accompanied by robust CD4+ and CD8+ T cell activation, compared to the homologous protein subunit regimen which led to a dominating IgG1 response with robust CD4+ T cell activation only. With the heterologous regimens, the IgG1:IgG2c ratios were reflective of their priming vaccine, a potential impact of immunological imprinting. However, in the heterologous regimens, robust cellular responses were only achieved in animals which had received a priming mRNA/LNP vaccine and not in those which were primed with the adjuvanted protein vaccine. This regimen resulted in superior CD4+ T cell activation as compared to the homologous mRNA/LNP regimen, while maintaining similar levels of CD8+ T cells. This study illustrates the potential for different immunological profiles to be induced by different heterologous vaccination regimens, which may impact long-term outcomes in human populations, such as the waning immunity observed for SARS-CoV-2.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Renner TM, Agbayani G, Azizi H, et al. Heterologous vs. homologous vaccine regimens: Sulfated lactosyl archaeol (SLA) archaeosome-adjuvanted SARS-CoV-2 spike protein boost following an mRNA/LNP prime induces robust and balanced immune responses. Vaccine. 2026. PMID: 41505874. doi:10.1016/j.vaccine.2025.128182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。